In a nutshell This article reviewed different options for first-line treatment for Hodgkin lymphoma (HL). Some background Treatment for patients with HL has become more individualized. Treatment strategies have been adapted to disease risk, and how well patients respond to initial treatment. The goal of these approaches is to reduce side effects...
Read MoreCurrent disease status-First occurrence of the lymphoma Posts on Medivizor
Searching for patients with untreated small lymphocytic lymphoma to test combined immunotherapy
In a nutshell This phase 2 study is evaluating the effectiveness of a new combination therapy for small lymphocytic lymphoma (SLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is recruiting in Rochester, New York, US. The details Typical treatments for SLL include...
Read MoreReviewing the risk of neutropenia after first-line treatment for advanced Hodgkin lymphoma
In a nutshell This article reviewed the risk of patients with advanced Hodgkin lymphoma (HL) developing neutropenia after first-line treatment. This study concluded that this condition can be a serious complication for these patients. Some background The most commonly used frontline chemotherapy regimens for advanced HL are ABVD (doxorubicin,...
Read MoreEvaluating RBD chemotherapy for recurrent or non-responsive non-Hodgkin lymphoma
In a nutshell This study evaluated how safe and effective RBD (rituximab, bendamustine, and dexamethasone) chemotherapy was for patients with B-cell non-Hodgkin lymphoma (NHL). This study concluded that this new regimen showed promising effectiveness for these patients. Some background Chemoimmunotherapy remains the standard first-line treatment...
Read MoreEvaluating rituximab plus lenalidomide for first-line treatment of follicular lymphoma
In a nutshell This study evaluated the effectiveness of rituximab (Rituxan) alone or with lenalidomide (Revlimid) for the first-line treatment of follicular lymphoma (FL). This study concluded that rituximab plus lenalidomide was effective and well-tolerated in these patients. Some background Immunochemotherapy is the current standard...
Read MoreEvaluating high-dose etoposide before stem cell transplantation for patients with unresponsive diffuse large B cell lymphoma
In a nutshell This study evaluated the outcomes of patients with unresponsive diffuse B-cell lymphoma (DLBCL) after treatment with high-dose etoposide (Etopophos) and a stem cell transplant (SCT). This study concluded that this regimen was effective for some of these patients, namely those who responded to etoposide treatment. Some background DLBCL is...
Read MoreLooking for young patients with non-Hodgkin’s lymphoma to test a treatment combination
In a nutshell This phase 3 trial is comparing the effectiveness of ibrutinib (Imbruvica) plus chemotherapy versus chemotherapy alone in children and young adults with B-cell non-Hodgkin’s lymphoma (NHL). The main outcome to be measured will be survival without cancer returning, growing or spreading. The details Ibrutinib is a targeted therapy...
Read MoreEvaluating the long-term outcomes of low-dose radiation therapy for early-stage nodular lymphocyte-predominant Hodgkin lymphoma
In a nutshell This study evaluated the effectiveness of radiation, chemotherapy, or both for the treatment of early-stage nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL). This study concluded that long-term outcomes were favorable across all treatment approaches. Some background NLPHL is a rare subtype of non-Hodgkin's lymphoma....
Read MoreCombination of ublituximab, umbralisib and ibrutinib for patients with leukemia and lymphoma
In a nutshell This study aimed to investigate the safety and effectiveness of ublituximab, umbralisib and ibrutinib combination in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). This study concluded that this combination appears safe and effective for these patients. Some background Patients...
Read MoreReviewing treatment options for patients with Hodgkin lymphoma
In a nutshell This article reviewed new developments in treatments for patients with Hodgkin lymphoma (HL). Some background For most patients with HL, conventional treatments such as chemotherapy are effective. However, about 50 – 60% of patients have cancer come back (relapse) or become resistant to treatment (refractory). High-dose...
Read MoreEvaluating rituximab plus lenalidomide for recurrent or non-responsive indolent non-Hodgkin lymphoma
In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) plus lenalidomide (Revlimid) for patients with recurrent or non-responsive non-Hodgkin’s lymphoma (NHL). This study concluded that lenalidomide was well-tolerated and improved the effectiveness of rituximab in these patients. Some background Follicular...
Read MoreOfatumumab to treat previously untreated follicular lymphoma
In a nutshell This study aimed to investigate the safety and effectiveness of ofatumumab in patients with untreated, advanced stage follicular lymphoma. This study concluded that ofatumumab is safe and effective in these patients. Some background Rituximab (Rituxan) is a targeted therapy that has proven effective in treating...
Read More
